EP. 3 Treatment Selection in Metastatic and Castration Resistant Prostate Cancer: Optimizing Outcomes and Preserving Patient Quality of Life
EP. 5 Targeting the Androgen Receptor Pathway and Overcoming Treatment Resistance in Advanced Prostate Cancer
EP. 6 Emerging AR Targeting Agents and CDK4/6 Inhibitors in Metastatic Prostate Cancer and Potential Impact on the Treatment Landscape
EP. 7 Multidisciplinary Collaboration and Expert Insights in the Management of Advanced Prostate Cancer
The UroOnc Minute: Cribriform Histology in Prostate Cancer, With Tyler Seibert, MD, PhDByAdam B. Weiner, MD,Tyler Seibert, MD, PhDAugust 21st 2026
Mary Dunn, MSN, NP-C, OCN, RN, on advances reshaping advanced prostate cancer careByMary Dunn, MSN, NP-C, OCN, RNAugust 20th 2026
Bringing POTOMAC Data Into Community Urology Practice for High-Risk NMIBCByNeal D. Shore, MD, FACS,Chandler Park, MDAugust 19th 2026
POTOMAC Subgroup Data: Cystectomy Risk and Rare Adverse Events in NMIBCByNeal D. Shore, MD, FACS,Chandler Park, MDAugust 19th 2026